TWI867526B - Glp1醫藥組合物 - Google Patents

Glp1醫藥組合物 Download PDF

Info

Publication number
TWI867526B
TWI867526B TW112117510A TW112117510A TWI867526B TW I867526 B TWI867526 B TW I867526B TW 112117510 A TW112117510 A TW 112117510A TW 112117510 A TW112117510 A TW 112117510A TW I867526 B TWI867526 B TW I867526B
Authority
TW
Taiwan
Prior art keywords
fluoro
composition
amount
methyl
methylcyclopropyl
Prior art date
Application number
TW112117510A
Other languages
English (en)
Chinese (zh)
Other versions
TW202410894A (zh
Inventor
李 喬瑟夫 伯恩斯
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202410894A publication Critical patent/TW202410894A/zh
Application granted granted Critical
Publication of TWI867526B publication Critical patent/TWI867526B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW112117510A 2022-05-11 2023-05-11 Glp1醫藥組合物 TWI867526B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340,591 2022-05-11

Publications (2)

Publication Number Publication Date
TW202410894A TW202410894A (zh) 2024-03-16
TWI867526B true TWI867526B (zh) 2024-12-21

Family

ID=86732348

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112117510A TWI867526B (zh) 2022-05-11 2023-05-11 Glp1醫藥組合物
TW113144409A TW202508581A (zh) 2022-05-11 2023-05-11 Glp1醫藥組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113144409A TW202508581A (zh) 2022-05-11 2023-05-11 Glp1醫藥組合物

Country Status (16)

Country Link
US (1) US20250302809A1 (enExample)
EP (1) EP4522129A1 (enExample)
JP (1) JP7767651B2 (enExample)
KR (1) KR20250002778A (enExample)
CN (1) CN119173255A (enExample)
AR (1) AR129296A1 (enExample)
AU (1) AU2023269995A1 (enExample)
CA (1) CA3253043A1 (enExample)
CL (1) CL2024003392A1 (enExample)
CO (1) CO2024015285A2 (enExample)
DO (1) DOP2024000232A (enExample)
IL (1) IL316629A (enExample)
MX (1) MX2024013839A (enExample)
PE (1) PE20251285A1 (enExample)
TW (2) TWI867526B (enExample)
WO (1) WO2023220109A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025108361A1 (zh) * 2023-11-21 2025-05-30 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI753946B (zh) * 2016-09-26 2022-02-01 日商中外製藥股份有限公司 具有ｇｌｐ-１受體促效作用的吡唑并吡啶衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520398A (ja) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2662748A1 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
TW202446384A (zh) 2018-12-07 2024-12-01 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
ES3040117T3 (en) 2020-09-09 2025-10-28 Crinetics Pharmaceuticals Inc Formulations of a somatostatin modulator
IL316478A (en) 2022-05-11 2024-12-01 Lilly Co Eli GLP1 tablet preparations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI753946B (zh) * 2016-09-26 2022-02-01 日商中外製藥股份有限公司 具有ｇｌｐ-１受體促效作用的吡唑并吡啶衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 王如意, and 劉怡. "噴霧乾燥分散體的研究進展." 中國新藥雜誌 27.12 (2018): 1357-1363. *

Also Published As

Publication number Publication date
CL2024003392A1 (es) 2025-03-14
PE20251285A1 (es) 2025-05-14
AR129296A1 (es) 2024-08-07
US20250302809A1 (en) 2025-10-02
KR20250002778A (ko) 2025-01-07
DOP2024000232A (es) 2024-12-30
EP4522129A1 (en) 2025-03-19
JP7767651B2 (ja) 2025-11-11
CN119173255A (zh) 2024-12-20
TW202508581A (zh) 2025-03-01
WO2023220109A1 (en) 2023-11-16
TW202410894A (zh) 2024-03-16
CA3253043A1 (en) 2023-11-16
CO2024015285A2 (es) 2024-11-28
IL316629A (en) 2024-12-01
JP2025515706A (ja) 2025-05-20
MX2024013839A (es) 2024-12-06
AU2023269995A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
TWI867526B (zh) Glp1醫藥組合物
JP4780522B2 (ja) フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
TWI564008B (zh) 難溶性藥物之溶解性改善製劑
JP2021178871A (ja) エンザルタミドの製剤
US10098843B2 (en) Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
EA028009B1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
TW201446286A (zh) 抗病毒化合物之固態分散調製劑
EP2293781A1 (en) Granulation of active pharmaceutical ingredients
AU2023269191A1 (en) Glp1 tablet compositions
TW200848056A (en) Solid dispersion of a neurokinin antagonist
CN1610539A (zh) 含有5ht1受体激动剂的药物组合物
JPWO2019230937A1 (ja) 溶出性に優れた経口固形製剤
EP2219614A1 (en) Pharmaceutical composition of orlistat
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤